Clopimozide

This classification denotes a dopamine antagonist with the molecular formula C28H28ClF2N3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7C6TA32SD2, chemically known as 5-chloro-1-(4-(4,4-bis(p-fluorophenyl)butyl)-4-piperidyl)-2-benzimidazolinone but generally known as clopimozide, which bears US NIH Compound Identifier 65449. European Medicines Agency schedules Clopimozide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06740MIG. The term CLOPIMOZIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 29, No. 10 1975, List 15). CLOPIMOZIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule clopimozide under HS 29333999 and SITC 51574. As of Q4 2014, CLOPIMOZIDE remains the US FDA Preferred Term for this commodity. Clopimozide bears US NLM identifiers UMLS ID C0055934 and NCI Concept Code C77571. SMILES: CLC1CC2[NH]C(=O)N(C3CCN(CC3)CCCC(C3CCC(F)CC3)C3CCC(F)CC3)C2CC1.